share_log

Needham Reiterates Buy on CRISPR Therapeutics, Maintains $90 Price Target

Moomoo 24/7 ·  Apr 11 06:38

Needham analyst Gil Blum reiterates CRISPR Therapeutics (NASDAQ:CRSP) with a Buy and maintains $90 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment